Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2001 2
2004 3
2005 2
2006 3
2007 1
2008 4
2009 5
2010 1
2011 2
2013 2
2014 2
2016 2
2018 1
2021 1
2022 2
2023 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Olmesartan Reduces New-onset Atrial Fibrillation and Atrial Fibrillation Burden after Dual-chamber Pacemaker Implantation in Atrioventricular Block Patients.
Zhang H, Pan C, Zhang J, Zhu LL, Huang K, Zhong Y, Hu ZY. Zhang H, et al. Chin Med J (Engl). 2016 Sep 20;129(18):2143-8. doi: 10.4103/0366-6999.189924. Chin Med J (Engl). 2016. PMID: 27625082 Free PMC article. Clinical Trial.
Moreover, olmesartan group had smaller values of maximal P-wave durations and P-wave dispersion (PD) after 24 months follow-up compared with the control group (109.5 7.4 ms vs. 113.4 7.1 ms, P = 0.00; and 40.6 4.5 ms vs. 43.3 4.4 ms, P = 0.02, respectively). …
Moreover, olmesartan group had smaller values of maximal P-wave durations and P-wave dispersion (PD) after 24 months follow-up …
Olmesartan induces renoprotective effects by stimulating angiotensin type 2 receptors and reducing oxidative stress in diabetic nephropathy.
Jo F, Morimoto S, Nakahigashi M, Kusabe M, Someya K, Morita T, Jo H, Imada T, Kosaki A, Toyoda N, Nishikawa M, Iwasaka T. Jo F, et al. Kidney Blood Press Res. 2011;34(6):418-23. doi: 10.1159/000328330. Epub 2011 Jun 28. Kidney Blood Press Res. 2011. PMID: 21709422
In the present study, we investigated the role of angiotensin type 2 (AT(2)) receptors on the renoprotective effects of olmesartan in diabetic nephropathy. METHODS: Six-week-old mice were treated with streptozotocin and divided into four groups: the OLM group (mice treated …
In the present study, we investigated the role of angiotensin type 2 (AT(2)) receptors on the renoprotective effects of olmesartan in …
Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis.
Tanigawara Y, Yoshihara K, Kuramoto K, Arakawa K. Tanigawara Y, et al. Drug Metab Pharmacokinet. 2009;24(4):376-88. doi: 10.2133/dmpk.24.376. Drug Metab Pharmacokinet. 2009. PMID: 19745564 Free article. Clinical Trial.
A two-way crossover study of olmesartan medoxomil and azelnidipine was conducted in 29 patients with mild to moderate essential hypertension. ...No patient was found to have a high E(max) to one agent who also had a high E(max) to the other. In conclusion, the effects of …
A two-way crossover study of olmesartan medoxomil and azelnidipine was conducted in 29 patients with mild to moderate essential hyper …
Dried Urine Spot Analysis for assessing cardiovascular drugs exposure applicable in spaceflight conditions.
Derobertmasure A, Kably B, Justin J, De Sousa Carvalho C, Billaud EM, Boutouyrie P. Derobertmasure A, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Mar 15;1219:123539. doi: 10.1016/j.jchromb.2022.123539. Epub 2022 Dec 8. J Chromatogr B Analyt Technol Biomed Life Sci. 2023. PMID: 36867996
Physiological changes during spaceflight could have severe implications on drug pharmacokinetics and pharmacodynamics (PK/PD). However, limitations exist for the implementation of drug studies due to the requirements and constraints of this extreme environment. Therefore, …
Physiological changes during spaceflight could have severe implications on drug pharmacokinetics and pharmacodynamics (PK/PD). Howeve …
In Vivo Dopamine Neuron Imaging-Based Small Molecule Screen Identifies Novel Neuroprotective Compounds and Targets.
Kim GJ, Mo H, Liu H, Okorie M, Chen S, Zheng J, Li H, Arkin M, Huang B, Guo S. Kim GJ, et al. Front Pharmacol. 2022 Mar 18;13:837756. doi: 10.3389/fphar.2022.837756. eCollection 2022. Front Pharmacol. 2022. PMID: 35370735 Free PMC article.
Parkinson's disease (PD) is the second most common neurodegenerative disorder with prominent dopamine (DA) neuron degeneration. PD affects millions of people worldwide, but currently available therapies are limited to temporary relief of symptoms. ...
Parkinson's disease (PD) is the second most common neurodegenerative disorder with prominent dopamine (DA) neuron degeneration. PD …
Improvement of stunned myocardium in dogs with olmesartan, an angiotensin II type 1 receptor antagonist, is independent of type 2 receptors.
Kano S, Satoh K, Kaneta S, Ichihara K. Kano S, et al. Pharmacology. 2008;82(1):22-9. doi: 10.1159/000127364. Epub 2008 Apr 22. Pharmacology. 2008. PMID: 18434761
In addition, the plasma level of angiotensin II was significantly increased by olmesartan. PD123319, a selective AT2 receptor antagonist, however, did not modify the effect of olmesartan on the cardiac contraction. The hypertensive response to exogenous angiotensin …
In addition, the plasma level of angiotensin II was significantly increased by olmesartan. PD123319, a selective AT2 receptor antagon …
Gateways to clinical trials.
Tomillero A, Moral MA. Tomillero A, et al. Methods Find Exp Clin Pharmacol. 2009 Dec;31(10):661-700. Methods Find Exp Clin Pharmacol. 2009. PMID: 20140276
[Methoxy-(11)C]PD-153035, 2-Methoxyestradiol; Adalimumab, Adecatumumab, Adefovir dipivoxil, ADH-1, ADX-10059, Aflibercept, AIR-human growth hormone, Aliskiren fumarate, AMG-221, Amlodipine besylate/olmesartan medoxomil, Aprepitant; Bavituximab, Bevacizumab, Bexarote …
[Methoxy-(11)C]PD-153035, 2-Methoxyestradiol; Adalimumab, Adecatumumab, Adefovir dipivoxil, ADH-1, ADX-10059, Aflibercept, AIR-human …
Gateways to clinical trials.
Tomillero A, Moral MA. Tomillero A, et al. Methods Find Exp Clin Pharmacol. 2009 Oct;31(8):541-57. Methods Find Exp Clin Pharmacol. 2009. PMID: 19967103
[Methoxy-11c]PD-153035; Afamelanotide, Agalsidase beta, Alemtuzumab, Alkaline phosphatase, Amlodipine, Anecortave acetate, Apixaban, Aripiprazole, Atomoxetine hydrochloride; Bevacizumab, Bortezomib, Bosentan, Botulinum toxin type B, Brimonidine tartrate/timolol maleate, Br …
[Methoxy-11c]PD-153035; Afamelanotide, Agalsidase beta, Alemtuzumab, Alkaline phosphatase, Amlodipine, Anecortave acetate, Apixaban, …
Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR. Bayés M, et al. Methods Find Exp Clin Pharmacol. 2004 Oct;26(8):639-63. Methods Find Exp Clin Pharmacol. 2004. PMID: 15605126
This issue focuses on the following selection of drugs: Abiraterone acetate, Ad5CMV-p53, adefovir dipivoxil, AE-941, ambrisentan, aripiprazole, atomoxetine hydrochloride, atrasentan; BCH-10618, bimatoprost, BMS-184476, BMS-275183, BMS-387032, botulinum toxin type B, BR-1, BR96-Do …
This issue focuses on the following selection of drugs: Abiraterone acetate, Ad5CMV-p53, adefovir dipivoxil, AE-941, ambrisentan, aripiprazo …
33 results